PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation
Titel:
PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation
Auteur:
Cortes, Jorge E. Kim, Dong-Wook Pinilla, Javier Paquette, Ronald le Coutre, Philipp D. Chuah, Charles Nicolini, Franck E. Apperley, Jane F. Jean Khoury, H. Talpaz, Moshe DiPersio, John F. DeAngelo, Daniel J Rea, Delphine Abruzzese, Elisabetta Mueller, Martin C. Baccarani, Michele Gambacorti-Passerini, Carlo Turner, Christopher D. Haluska, Frank Kantarjian, Hagop M.